Anzeige
Erschienen in:
01.12.2015 | Original Article
The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma
Erschienen in: Surgery Today | Ausgabe 12/2015
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) are prognostic factors for hepatocellular carcinoma (HCC). The impact of these tumor markers in recurrent HCC on the prognosis remains to be fully elucidated.
Methods
Two hundred and seventeen patients whose AFP and DCP levels were measured at recurrence were enrolled in the present study. AFP levels >10 ng/mL and DCP levels ≥40 mAU/mL were defined as AFP positive (AFP+) and DCP positive (DCP+), respectively. The patterns of tumor markers were scored as AFP−/DCP−, 0; AFP+/DCP− or AFP−/DCP+, 1 and AFP+/DCP+, 2.
Results
The median survival period after recurrence in patients with a score of 2 (26.6 months) was significantly lower than that in patients with scores of 1 or 0 (43.5 months, P < 0.01; 75.3 months, P < 0.01, respectively). A multivariate analysis showed that a tumor marker score of 2 at recurrence was an independent predictor for poor survival after recurrence (hazard ratio 2.12, P = 0.03). The prognosis after recurrence in the patients with a decreased tumor maker score was significantly better than that in the patients with no change in the tumor marker score compared to the primary surgery (P = 0.048).
Conclusions
The present study shows that measurements of both AFP and DCP are useful for predicting the prognosis of recurrent HCC.